After inclusion, information and inference: Reporting on clinical trials results after 15 years of monitoring inclusion of women

Journal of Women's Health

Volumn 20, Issue 6, 2011, Pages 829-836

  Foulkes, Mary A ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); FEMALE; HUMAN; NATIONAL HEALTH ORGANIZATION; PATIENT PARTICIPATION; PRIORITY JOURNAL; PUBLICATION; RESEARCH SUBJECT; REVIEW; SEX DIFFERENCE; WOMEN'S HEALTH;

BIBLIOMETRICS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; NATIONAL INSTITUTES OF HEALTH (U.S.); RESEARCH SUBJECTS; SEX DISTRIBUTION; UNITED STATES; WOMEN'S HEALTH;

EID: 79959320053     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2527     Document Type: Review

References (38)

1. Freedman L, Simon R, Foulkes MA, et al. Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 - The perspective of NIH clinical trialists. Control Clin Trials 1995;16:277-285.
2. Pinn VW, Roth C, Bates A, Wagner R, Jarema A. 2009 DHHS monitoring adherence to the NIH policy on the inclusion of women and minorities as subjects in clinical research: Comprehensive report-Tracking of human subjects research as reported in fiscal year 2007 and fiscal year 2008. Bethesda, MD. Available at orwh.od.nih.gov/inclusion/2009AnnualTrackingInclusionComprehensiveRpt.pdf
3. National Institutes of Health Instructions to reviewers for evaluating research involving human subjects in grant and cooperative agreement applications. Available at grants. nih.gov/grants/peer/hs-review-inst.pdf
4. Russek-Cohen E, Simon R. Evaluating treatment when a gender by treatment interaction may exist. Stat Med 1997;16:455-464. (Pubitemid 27073013)
5. U.S. Department of Health and Human Services, National Institutes of Health. NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Notice. Fed Reg 1994;59:14508-14513.
6. Geller SE, Adams MG, Carnes M. Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials. J Womens Health 2006;15:1123-1132.
7. Johnson SM, Karvonen CA, Phelps CL, et al. Assessment of analysis by gender in the Cochrane reviews as related to treatment of cardiovascular disease. J Womens Health 2003;12:449-557.
8. Meinert CL, Gilpin AK, Ünalp A, et al. Gender representation in trials. Control Clin Trials 2000;21:462-475.
9. Schulz KF, Altman D, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Obstet Gynecol 2010;115:1063-1070.
10. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? JAMA 1993;270:2598-2601.
11. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994;272:123-128.
12. Oxman AD. Checklists for review articles. BMJ 1994;309:648-651. (Pubitemid 24281192)
13. Goodman SN, Berlin J, Fletcher SW, et al. Manuscript quality before and after peer review and editing at Annals of Internal Medicine. Ann Intern Med 1994;121:11-21.
14. Shultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: Dimensions of methodologic quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.
15. Altman DG. Better reporting of randomized controlled trials: The CONSORT statement. BMJ 1996;313:570-571. (Pubitemid 26293636)
16. Verhagen AP, de Vet HCW, de Bie RA, Boers M, van den Brandt PA. The art of quality assessment of RCTs included in systematic reviews. J Clin Epidemiol 2001;54:651-654. (Pubitemid 32594850)
17. Jatoi A, Kahanic SP, Frytak S, et al. Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: Preliminary results and suggestions for future study designs. Supportive Care Cancer 2005;13:66-69. (Pubitemid 40193067)
18. ALLHAT Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000;283:1967-1975.
19. Benson CA, Vaida F, Havlir DV, et al. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis 2006;194:1309-1318. (Pubitemid 44630977)
20. Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005;42:1184-1193. (Pubitemid 43112686)
21. ENRICHD Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction. JAMA 2003;289:3106-3116.
22. Rockey DC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy. Lancet 2005;365:305-311. (Pubitemid 40139107)
23. Engelman RM, Pleet AB, Rousou JA, et al. Influence of cardiopulmonary bypass perfusion temperature on neurologic and hematologic function after coronary artery bypass grafting. Ann Thoracic Surg 1999;67:1547-1556. (Pubitemid 29301290)
24. Journal of the National Cancer Institute Instructions to Authors. Available at www.oxfordjournals.org/our-journals/jnci/for-authors/index.html
25. Sherer R, Crawley B. Reporting of randomized clinical trial descriptors and use of structured abstracts. JAMA 1998;280:269-272. (Pubitemid 28493904)
26. Powderly WM, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-705.
27. Boutron I, Estellat C, Guittet L, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: A systematic review. PLoSMed 2006;3:e425.
28. Lewis SC, Warlow CP. How to spot bias and other potential problems in randomised controlled trials. J Neurol Neurosurg Psychiatry 2004;75:181-187. (Pubitemid 38183520)
29. Toole JF, Malinow MR, Chambless LE. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death. JAMA 2004;291:565-575.
30. Byar DB. Assessing apparent treatment-covariate interactions in randomized clinical trials. Stat Med 1985;4:255-263.
31. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
32. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA 2006;295:2003-217.
33. Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med 2010;361:712-717.
34. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: Rationale, conduct, and reporting. BMJ 2010;340:c221.
35. Rochon PA, ClarkJP, Binns MA, Patel V, Gurwitz JH. Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction. Can Med Assoc J 1998;159:321-327. (Pubitemid 28433101)
36. Chilet-Rosell E, Ruiz-Cantero MT, Horge JF. Women's health and gender-based clinical trials on etoricoxib: Methodological gender bias. J Public Health 2009;31:434-445.
37. Holdcroft A. Gender bias in research: How does it affect evidence-based medicine? JR Soc Med 2007;100:2-3.
38. Ruiz-Cantero MT, Vives-Cases C, Artazcoz L, et al. A framework to analyse gender bias in epidemiological research. J Epidemiol Community Health 2007;61(suppl 2):46-53.